Back to Search
ALAIN MITA, MD
MD
Medical Oncology Physician
NPI: 1285602565IndividualAccepts Medicare
Specialties, Licenses & Credentials
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
M3028(TX)
CMS Specialties
PrimaryHEMATOLOGY/ONCOLOGY
Education
OTHER
Class of 1992
Research & Publications (20)
Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors.
PMID 19147780·Clin Cancer Res·2009
3-trial
Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics.
PMID 18698017·Clin Cancer Res·2008
6-review
Phase I and pharmacokinetic study of AI-850, a novel microparticle hydrophobic drug delivery system for paclitaxel.
PMID 17545535·Clin Cancer Res·2007
3-trial
Phase I and pharmacokinetic study of tasidotin hydrochloride (ILX651), a third-generation dolastatin-15 analogue, administered weekly for 3 weeks every 28 days in patients with advanced solid tumors.
PMID 16951240·Clin Cancer Res·2006
3-trial
Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function.
PMID 16391300·J Clin Oncol·2006
3-trial
Development of rationally designed, target-based agents for the treatment of advanced colorectal cancer.
PMID 15285818·Clin Colorectal Cancer·2004
6-review
Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulation.
PMID 19583815·J Cell Mol Med·2010
7-preclinical
The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents.
PMID 19381454·Target Oncol·2009
6-review
Potential feasibility of early bone marrow cell injection into the spleen for creating functional hepatocytes.
PMID 19384160·Transplantation·2009
7-preclinical
Phase I and pharmacokinetic study of trabectedin as a 1- or 3-hour infusion weekly in patients with advanced solid malignancies.
PMID 19417019·Clin Cancer Res·2009
3-trial
Unique inbred strain MSM/Ms established from the Japanese wild mouse.
PMID 19448335·Exp Anim·2009
7-preclinical
Toward improving human islet isolation from younger donors: rescue purification is efficient for trapped islets.
PMID 19476205·Cell Transplant·2009
8-other
Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors.
PMID 18795291·Cancer Chemother Pharmacol·2009
3-trial
Targeting the mTOR pathway using deforolimus in cancer therapy.
PMID 19374536·Future Oncol·2009
6-review
A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies.
PMID 19509177·Clin Cancer Res·2009
3-trial
Phase I study of paclitaxel poliglumex administered weekly for patients with advanced solid malignancies.
PMID 19034451·Cancer Chemother Pharmacol·2009
3-trial
Interval time coding by neurons in the presupplementary and supplementary motor areas.
PMID 19252498·Nat Neurosci·2009
7-preclinical
Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumors.
PMID 18798063·Cancer Invest·2008
3-trial
Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin.
PMID 18824702·J Clin Oncol·2008
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 7703 FLOYD CURL DR, MC 7977
SAN ANTONIO, TX 78229 - Phone
- (210) 257-1400
Quick Facts
- NPI
- 1285602565
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 34
- Publications
- 20
Are you this provider?
Claim Your Profile